Skip to content

Outpatient Exclusive Human Milk Diet for Single Infant With Complex Congenital Heart Disease

A Single Patient Observational Trial of an Exclusive Human Milk Diet to Provide and Evaluate Growth in a Single Infant at Home With Complex Congenital Heart Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04231630
Enrollment
1
Registered
2020-01-18
Start date
2019-11-20
Completion date
2020-05-30
Last updated
2020-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Delay

Brief summary

A single patient observational trial to evaluate growth velocity and clinical outcomes of an infant status post cardiac surgery who has failed to grow well and demonstrated intolerance to cow milk-based and elemental formulas and fortifiers on a 100% human milk diet including a human milk based human milk fortifier formulated for term infants fluid restricted due to surgically correctable congenital conditions.

Detailed description

A single patient observational study to evaluate growth velocity and clinical outcomes of an infant status post cardiac surgery who has failed to grow well and demonstrated intolerance to cow milk-based and elemental formulas and fortifiers on a 100% human milk diet. Human milk is defined as expressed human milk or donor milk and its derivatives, human milk-based fortifier and human milk caloric fortifier. The study hypothesis is that this infant if fed an exclusive human milk diet will have improved growth in part due to data greater tolerability of the diet. It is estimated that the study will require 90 days to complete. Growth in safety observations will be collected only during the time the patient is receiving the diet. The primary objective is to evaluate growth velocity (weight velocity \[g/kg/day\] of a single infant receiving a 100% human milk diet including a human milk based human milk fortifier formulated for term infants who are fluid restricted due to surgically correctable congenital conditions. This will be compared to the infant's growth velocity prior to the initiation of said diet.

Interventions

OTHERProlacta

Will receive outpatient supplementation with donor human milk product added to mother's own milk

Sponsors

Prolacta Bioscience
CollaboratorINDUSTRY
University of Texas at Austin
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
6 Months to 1 Years
Healthy volunteers
No

Inclusion criteria

* Complex congenital heart disease in presence of poor linear and head circumference growth and unable to tolerate cow's milk protein

Exclusion criteria

* n/a

Design outcomes

Primary

MeasureTime frameDescription
Growththrough study completion, approximately 6 monthsWeight velocity

Secondary

MeasureTime frameDescription
Linear growththrough study completion, approximately 6 monthsLength gain
Head circumference growththrough study completion, approximately 6 monthsHead circumference growth

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026